New drug cocktail aims to shrink Hard-to-Treat cancers
NCT ID NCT07111546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75, in good physical condition, and have a life expectancy of at least 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LBL-024 (an experimental drug) combined with cisplatin, gemcitabine, and bevacizumab
What this could lead to
If successful, this combination could shrink tumors in people with advanced solid cancers, offering a new treatment option.
What could go wrong
This is an early Phase 2 trial with only 140 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, Jiangxi, 330029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sir Run Run Shaw Hospital (SRRSH) Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310016, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITINGNanning, Guangxi, 530021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xiangyang Central Hospital
RECRUITINGXiangyang, Hubei, 441106, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhongshan Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••